The right bug in the right place: opportunities for bacterial vaginosis treatment
Abstract Bacterial vaginosis (BV) is a condition in which the vaginal microbiome presents an overgrowth of obligate and facultative anaerobes, which disturbs the vaginal microbiome balance. BV is a common and recurring vaginal infection among women of reproductive age and is associated with adverse...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-05-01
|
| Series: | npj Biofilms and Microbiomes |
| Online Access: | https://doi.org/10.1038/s41522-022-00295-y |
| _version_ | 1811304826983677952 |
|---|---|
| author | Shengru Wu Luisa Warchavchik Hugerth Ina Schuppe-Koistinen Juan Du |
| author_facet | Shengru Wu Luisa Warchavchik Hugerth Ina Schuppe-Koistinen Juan Du |
| author_sort | Shengru Wu |
| collection | DOAJ |
| description | Abstract Bacterial vaginosis (BV) is a condition in which the vaginal microbiome presents an overgrowth of obligate and facultative anaerobes, which disturbs the vaginal microbiome balance. BV is a common and recurring vaginal infection among women of reproductive age and is associated with adverse health outcomes and a decreased quality of life. The current recommended first-line treatment for BV is antibiotics, despite the high recurrence rate. Live biopharmaceutical products/probiotics and vaginal microbiome transplantation (VMT) have also been tested in clinical trials for BV. In this review, we discuss the advantages and challenges of current BV treatments and interventions. Furthermore, we provide our understanding of why current clinical trials with probiotics have had mixed results, which is mainly due to not administering the correct bacteria to the correct body site. Here, we propose a great opportunity for large clinical trials with probiotic strains isolated from the vaginal tract (e.g., Lactobacillus crispatus) and administered directly into the vagina after pretreatment. |
| first_indexed | 2024-04-13T08:14:20Z |
| format | Article |
| id | doaj.art-11fcfefe19d5459a91ea6b485865ccff |
| institution | Directory Open Access Journal |
| issn | 2055-5008 |
| language | English |
| last_indexed | 2024-04-13T08:14:20Z |
| publishDate | 2022-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Biofilms and Microbiomes |
| spelling | doaj.art-11fcfefe19d5459a91ea6b485865ccff2022-12-22T02:54:50ZengNature Portfolionpj Biofilms and Microbiomes2055-50082022-05-018111110.1038/s41522-022-00295-yThe right bug in the right place: opportunities for bacterial vaginosis treatmentShengru Wu0Luisa Warchavchik Hugerth1Ina Schuppe-Koistinen2Juan Du3Centre for Translational Microbiome Research (CTMR), Department of Microbiology, Tumor, and Cell Biology, Karolinska InstitutetCentre for Translational Microbiome Research (CTMR), Department of Microbiology, Tumor, and Cell Biology, Karolinska InstitutetCentre for Translational Microbiome Research (CTMR), Department of Microbiology, Tumor, and Cell Biology, Karolinska InstitutetCentre for Translational Microbiome Research (CTMR), Department of Microbiology, Tumor, and Cell Biology, Karolinska InstitutetAbstract Bacterial vaginosis (BV) is a condition in which the vaginal microbiome presents an overgrowth of obligate and facultative anaerobes, which disturbs the vaginal microbiome balance. BV is a common and recurring vaginal infection among women of reproductive age and is associated with adverse health outcomes and a decreased quality of life. The current recommended first-line treatment for BV is antibiotics, despite the high recurrence rate. Live biopharmaceutical products/probiotics and vaginal microbiome transplantation (VMT) have also been tested in clinical trials for BV. In this review, we discuss the advantages and challenges of current BV treatments and interventions. Furthermore, we provide our understanding of why current clinical trials with probiotics have had mixed results, which is mainly due to not administering the correct bacteria to the correct body site. Here, we propose a great opportunity for large clinical trials with probiotic strains isolated from the vaginal tract (e.g., Lactobacillus crispatus) and administered directly into the vagina after pretreatment.https://doi.org/10.1038/s41522-022-00295-y |
| spellingShingle | Shengru Wu Luisa Warchavchik Hugerth Ina Schuppe-Koistinen Juan Du The right bug in the right place: opportunities for bacterial vaginosis treatment npj Biofilms and Microbiomes |
| title | The right bug in the right place: opportunities for bacterial vaginosis treatment |
| title_full | The right bug in the right place: opportunities for bacterial vaginosis treatment |
| title_fullStr | The right bug in the right place: opportunities for bacterial vaginosis treatment |
| title_full_unstemmed | The right bug in the right place: opportunities for bacterial vaginosis treatment |
| title_short | The right bug in the right place: opportunities for bacterial vaginosis treatment |
| title_sort | right bug in the right place opportunities for bacterial vaginosis treatment |
| url | https://doi.org/10.1038/s41522-022-00295-y |
| work_keys_str_mv | AT shengruwu therightbugintherightplaceopportunitiesforbacterialvaginosistreatment AT luisawarchavchikhugerth therightbugintherightplaceopportunitiesforbacterialvaginosistreatment AT inaschuppekoistinen therightbugintherightplaceopportunitiesforbacterialvaginosistreatment AT juandu therightbugintherightplaceopportunitiesforbacterialvaginosistreatment AT shengruwu rightbugintherightplaceopportunitiesforbacterialvaginosistreatment AT luisawarchavchikhugerth rightbugintherightplaceopportunitiesforbacterialvaginosistreatment AT inaschuppekoistinen rightbugintherightplaceopportunitiesforbacterialvaginosistreatment AT juandu rightbugintherightplaceopportunitiesforbacterialvaginosistreatment |